Search

Your search keyword '"Sedhom, Ramy"' showing total 479 results
Start Over Author "Sedhom, Ramy"
479 results on '"Sedhom, Ramy"'

11. iNUDGE: Integration of liquid biopsy based next generation gene sequencing in newly diagnosed NSCLC—A stepped wedge cluster randomized clinical trial.

Author

Martella, Anthony O., primary, Scholes, Dylan G., additional, Wileyto, E. Paul, additional, Tierney, Ann, additional, Hume, Meagan, additional, Roy, Megan, additional, Kazmi, Shayma Master, additional, D'Avella, Christopher, additional, Kerr, Samuel J., additional, Sedhom, Ramy, additional, Gabriel, Peter Edward, additional, Rendle, Katharine A., additional, Bekelman, Justin E., additional, Doucette, Abigail, additional, Boisseau, Leland, additional, Marmarelis, Melina Elpi, additional, and Aggarwal, Charu, additional

Published
2024
Full Text
View/download PDF

22. Outcomes With Limus- vs Paclitaxel-Coated Balloons for Percutaneous Coronary Intervention: Meta-Analysis of Randomized Controlled Trials.

Author

Sedhom, Ramy, Hamed, Mohamed, Elbadawi, Ayman, Mohsen, Amr, Swamy, Pooja, Athar, Ahmed, Bharadwaj, Aditya S., Prasad, Vinoy, Elgendy, Islam Y., and Alfonso, Fernando

Abstract

Randomized controlled trials (RCTs) examining the outcomes with limus drug-coated balloons (DCBs) vs paclitaxel DCBs were small and underpowered for clinical endpoints. This study sought to compare the angiographic and clinical outcomes with limus DCBs vs paclitaxel DCBs for percutaneous coronary intervention (PCI). An electronic search of Medline, EMBASE, and Cochrane databases was performed through January 2024 for RCTs comparing limus DCBs vs paclitaxel DCBs for PCI. The primary endpoint was clinically driven target lesion revascularization (TLR). The secondary endpoints were late angiographic findings. Summary estimates were constructed using a random effects model. Six RCTs with 821 patients were included; 446 patients received a limus DCB, and 375 patients received a paclitaxel DCB. There was no difference between limus DCBs and paclitaxel DCBs in the incidence of TLR at a mean of 13.4 months (10.3% vs 7.8%; risk ratio [RR]: 1.32; 95% CI: 0.84-2.08). Subgroup analysis suggested no significant interaction among studies for de novo coronary lesions vs in-stent restenosis (P interaction = 0.58). There were no differences in the risk of major adverse cardiovascular events, cardiac mortality, or target vessel myocardial infarction between groups. However, limus DCBs were associated with a higher risk of binary restenosis (RR: 1.89; 95% CI: 1.14-3.12), late lumen loss (mean difference = 0.16; 95% CI: 0.03-0.28), and a smaller minimum lumen diameter (mean difference = −0.12; 95% CI: −0.22 to −0.02) at late follow-up. In addition, late lumen enlargement occurred more frequently (50% vs 27.5%; RR: 0.59; 95% CI: 0.45-0.77) with paclitaxel DCBs. Among patients undergoing DCB-only PCI, there were no differences in the risk of clinically driven TLR and other clinical outcomes between limus DCBs and paclitaxel DCBs. However, paclitaxel DCBs were associated with better late angiographic outcomes. These findings support the need for future trials to establish the role of new-generation limus DCBs for PCI. [Display omitted] [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Global burden of cardiovascular disease attributable to smoking, 1990–2019: an analysis of the 2019 Global Burden of Disease Study

Author

Khan Minhas, Abdul Mannan, Sedhom, Ramy, Jean, Estelle D, Shapiro, Michael D, Panza, Julio A, Alam, Mahboob, Virani, Salim S, Ballantyne, Christie M, and Abramov, Dmitry

Abstract

The burden of cardiovascular disease (CVD) attributed to smoking declined worldwide between 1990 and 2019. The burden of smoking-attributed CVD was higher in men than in women in 2019. There were significant variations between different countries and regions such that Eastern Europe had the highest death rate and Andean Latin America had the lowest death rate in 2019. Also, countries with high socio-economic status had lower death rates from smoking-attributed CVD. This highlights the need for targeted interventions to reduce the burden of smoking-attributed CVD.The overall age-adjusted deaths from CVD attributed to smoking declined from 57.16/100 000 in 1990 to 33.03/100 000 in 2019.In 2019, ischaemic heart disease was the leading cause of smoking-attributed CVD deaths.

Published
2024
Full Text
View/download PDF

35. Health Care Contact Days Experienced by Decedents With Advanced GI Cancer

Author

Patel, Vishal R., primary, Ramesh, Vidhyalakshmi, additional, Tsai, Alexander K., additional, Sedhom, Ramy, additional, Westanmo, Anders D., additional, Blaes, Anne H., additional, Vogel, Rachel I., additional, Parsons, Helen M., additional, Hanna, Timothy P., additional, Ganguli, Ishani, additional, Dusetzina, Stacie B., additional, Rocque, Gabrielle B., additional, Booth, Christopher M., additional, and Gupta, Arjun, additional

Published
2023
Full Text
View/download PDF

46. Behavioural economic interventions to embed palliative care in community oncology (BE-EPIC): study protocol for the BE-EPIC randomised controlled trial

Author

Parikh, Ravi B, primary, Sedhom, Ramy, additional, Ferrell, William J, additional, Villarin, Katherine, additional, Berwanger, Kara, additional, Scarborough, Bethann, additional, Oyer, Randall, additional, Kumar, Pallavi, additional, Ganta, Niharika, additional, Sivendran, Shanthi, additional, Chen, Jinbo, additional, Volpp, Kevin G, additional, and Bekelman, Justin E, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results